Share
Services
Contact
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
123
MARGINAL CONTENT
Fresenius is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In fiscal year 2024, Fresenius generated €21.5 billion in annual revenue with around 176,000 employees (excluding Fresenius Medical Care). As a healthcare company focused on therapy, Fresenius offers system-critical products and services for leading therapies for the care of critically and chronically ill patients.
Our Mission
We save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.
Our Vision
We are the trusted, market-leading healthcare company that unites cutting-edge technology and human care to shape next-level therapies.
Our Principles form the basis of our company culture. They describe what we stand for and how we operate, collaborate, approach challenges and make decisions.
We serve patients beyond expectations
Bold in our ambitions. Turning ideas into actions.
We care for excellence
No compromise on quality. True north in mind.
We bring healthcare innovation to people
Learning with our customers and partners. Pushing therapies to the next level.
We live the power of One Team
Respectful collaboration. Empowering responsibility.
We act today for a better tomorrow
Over 100 years of heritage. Mindful of future needs and resources.
The Fresenius Group comprises the Operating Companies Fresenius Kabi and Fresenius Helios as well as the Investment Company Fresenius Medical Care.
Fresenius continuously develops its business areas. With the #FutureFresenius program, the focus will be on three therapy platforms:
With these platforms, Fresenius caters to major trends in healthcare and becomes a more therapy-focused company. The health and quality of life of patients who the company serves with high-quality, affordable products and services is at the core.
At Fresenius, the patient always comes first. For more than 100 years now we have been working to save lives and improve the quality of life of our critically and chronically ill patients. A clear focus on innovation and efficiency has helped us to make world-class therapies accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions. This is how Fresenius is contributing to medical progress and better patient care.
Success in our business is the key for investing in high-quality yet affordable healthcare. In this way we are meeting our social responsibility to help patients, while ensuring that Fresenius remains successful over the long term. As a global healthcare group with a diverse workforce, we are committed to an open and pluralistic society. We are convinced that extremism, populism and intolerance threaten the free and democratic basic order, our way of life and our prosperity.
Fresenius leads by recognizing important trends and developments early, then working with our partners to help shape healthcare systems. Aging populations and the expansion of healthcare provision in countries worldwide are driving demand for medical products and services, and Fresenius is excellently positioned for continuous and profitable growth in the future.
"Committed to Life" - We save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.
Contact
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 608-0
pr-fre@fresenius.com
Fresenius
1462
The Hirsch Pharmacy opens in Frankfurt am Main. The Fresenius family assumes ownership in the 19th century.
Fresenius
1912
The pharmacist Dr. Eduard Fresenius, proprietor of the Hirsch Pharmacy, establishes the pharmaceutical company Dr. E. Fresenius. He expands the pharmacy laboratory into a small manufacturing operation. Its main products are pharmaceutical specialties such as injection solutions, serologic reagents and Bormelin nasal ointment.
Fresenius
1933
The manufacturing company is separated from the Hirsch Pharmacy and moves to Bad Homburg, just outside of Frankfurt. Dr. Fresenius devotes more and more time to the company, which grows to around 400 employees.
Fresenius
1946
The unexpected death of Eduard Fresenius endangers the further existence of the pharmacy and manufacturing company, which now has only 40 employees.
Fresenius
1952
Else Fernau (later Else Kröner (*1925; †1988)), the foster daughter of Eduard Fresenius, assumes responsibility for the pharmacy and company after obtaining her degree in pharmacy studies.
Fresenius
1955
The infusion solutions product range is expanded.
Fresenius
1966
Fresenius starts to sell dialysis machines and dialyzers manufactured by various foreign companies and gains substantial market shares.
Fresenius
1974
Fresenius begins manufacturing infusion solutions and medical disposables in St. Wendel, in Germany's Saarland region. Today, Fresenius Medical Care produces highly innovative polysulfone dialyzers in the St. Wendel plant.
Fresenius
1979
Production of the A2008 dialysis machine begins in a newly acquired factory in Schweinfurt. The machine is awarded a gold medal at the Leipzig Trade Fair that year.
Fresenius
1982
The company is converted into a joint stock company. The Supervisory Board is headed by Else Kröner.
Fresenius
1983
Fresenius begins producing synthetic polysulfone fiber membranes for blood purification. These membranes still set the quality standards for dialyzers today.
Fresenius
1986
Fresenius launches preference shares on the Frankfurt stock exchange.
Fresenius
1990
Fresenius employs 5,200 people; total sales exceed 1 billion deutsche marks.
Fresenius Vamed
1994
With the acquisition of Hospitalia International, Fresenius enters the project business for developing hospitals and other healthcare facilities.Two years later, Fresenius acquires a majority stake in the hospital services provider VAMED AG.
Fresenius Medical Care
1996
In 1996, the merger of Fresenius' dialysis business with the U.S. dialysis provider National Medical Care resulted in the creation of Fresenius Medical Care, the world's leading dialysis provider. Its shares are traded on the Frankfurt and New York stock exchanges.
Fresenius
1997
Fresenius opens a highly modern production plant for infusion solutions in Friedberg, just north of Frankfurt.
Consolidated sales amount to approximately 7.5 billion deutsche marks.
Fresenius
1998
Fresenius moves into new headquarters in Bad Homburg. The company has nearly 39,000 employees worldwide.
Fresenius Kabi
1999
After acquiring the international nutrition business of Pharmacia & Upjohn the year before, Fresenius merges it with Fresenius Pharma to form a new company: Fresenius Kabi. Fresenius Kabi becomes the European leader in nutrition and infusion therapy, with subsidiaries and distributors worldwide.
At Fresenius Medical Care, the 100,000th dialysis machine comes off the production line.
Fresenius
2001
Fresenius acquires Wittgensteiner Kliniken AG, one of the major nationwide operators of private hospitals in Germany.
Fresenius, a health care group with worldwide operations and over 60,000 employees, achieves sales of around 7.3 billion euros.
Fresenius Medical Care
2003
With an output of more than 50 million dialyzers per year, Fresenius Medical Care sets a new record.
Fresenius Helios
2005
Fresenius acquires Helios, one of the top three private hospital operators in Germany.
Fresenius Medical Care
2006
Fresenius Medical Care takes over U.S. dialysis care provider Renal Care Group. Through its network of approximately 2,000 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to approximately 157,000 patients around the globe.
Fresenius
2007
Fresenius is converted into a European company (Societas Europaea, or SE). This allows Fresenius to act as a legal entity anywhere inside the European Union.
Fresenius Kabi
2008
Fresenius Kabi strengthens its business with intravenously administered generic drugs (I.V. generics) and expands into oncology drugs with the acquisition of the Indian company Dabur Pharma.
Fresenius Kabi enters the North American pharmaceuticals market, and becomes a globally leading company in the field of I.V. generics through the acquisition of the U.S.-based APP Pharmaceuticals.
Fresenius
2009
Fresenius SE's preferred shares are admitted into the DAX, which already includes Fresenius Medical Care shares.
Fresenius
2011
Conversion of all preference shares into ordinary shares in combination with a change of the company's legal form into a partnership limited by shares – Kommanditgesellschaft auf Aktien (KGaA). Fresenius SE becomes Fresenius SE & Co. KGaA.
Fresenius
2012
As Fresenius turns 100, the company is active in some 100 countries and has more than 160,000 employees.
Fresenius Medical Care produces the 500,000th dialysis machine.
Fresenius Medical Care
2013
Fresenius Medical Care produces its 1,000,000,000th dialyzer.
Fresenius Helios
2014
Fresenius Helios completes the acquisition of 41 hospitals and 13 outpatient facilities from Rhön-Klinikum AG. Fresenius Helios now owns 111 hospitals in Germany and is Europe's largest private hospital operator.
Fresenius also passes the milestone of 200,000 employees.
Fresenius Helios
2017
Fresenius Helios acquires Quirónsalud, Spain’s largest private hospital operator.
Fresenius Kabi
2019
Fresenius Kabi launches its first biosimilar Idacio®. Biosimilars are drugs that are highly similar to other approved biologic drugs.
Fresenius Medical Care acquires NxStage Medical, Inc. NxStage develops, produces and markets an innovative product portfolio of medical devices for use in home dialysis and critical care.
Fresenius
2023
The Operating Companies Fresenius Kabi and Fresenius Helios are at the center of the Group’s ambitions under #FutureFresenius. They are both geared for significant value creation and catering to system-critical areas of healthcare.
The company deconsolidates Fresenius Medical Care by changing Fresenius Medical Care’s legal form to a German Stock Corporation (“Aktiengesellschaft”).
Video
100 years of Fresenius
Fresenius has been working for over 100 years to improve the lives of seriously ill people around the world. This film, made on the occasion of the company's Centennial in 2012, tells the company's history through the stories of people who have been helped and are still being helped by Fresenius.
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced publication of its 2021 Global Annual Medical Report. Titled “Embracing the Complexity of Global Healthcare,” the report focuses on addressing healthcare complexities by driving meaningful advances in kidney disease care.
“The volume of thought leadership, ideas and expertise in the report demonstrates our company’s continued leadership in kidney care, our innovation through lifelong learning and our commitment to our patient-centered mission,” said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care.
The 2021 Global Annual Medical Report comprises 25 chapters by more than 40 authors from across the company. Six different sections each focus on a core theme of Fresenius Medical Care’s Clinical & Quality Agenda. An additional COVID-19 section is dedicated to the company’s ongoing efforts to address the pandemic.
The core themes are:
The 2021 Global Annual Medical Report is published by the Global Medical Office of Fresenius Medical Care. The full report is now available online at: https://www.freseniusmedicalcare.com/en/about-us/sustainability/medical-responsibility/
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
The price increase for hospital services in Germany has been set at 2.29% for 2022. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.
